Inflammatory mediators in endometriosis pathogenesis

Inflammatory mediators in endometriosis pathogenesis

Could proinflammatory Interleukin-32 be our new target?

Key Points


  • This research article examined the role of interleukin-32 (IL-32) in endometriosis pathogenesis.


  • IL-32 increased endometrial cells viability, proliferation and invasion thus might be involved in endometriosis.

What's done here:

  • Comparison of IL-32 levels in the peritoneal fluids between women with and without endometriosis
  • Endometrial cells viability, proliferation, and invasion in the presence and absence of IL-32 were investigated.
  • Experiments to determine the size of ectopic endometriotic lesions in IL-32 transgenic and wild-type mice with induced endometriosis.


  • IL-32 concentration in peritoneal fluid was significantly higher in patients with advanced stage endometriosis than the controls.
  • Endometrial cells treated with IL-32 caused increases in cellular viability, proliferating cell nuclear antigen (PCNA) expression, and invasiveness.
  • IL-32 transgenic mice had larger ectopic endometrial lesions than wild-type mice.


  • The study cannot conclude if IL-32 is the main regulator or only part of a proinflammatory cytokines network causing endometriosis progression.
  • More studies are needed to use information regarding IL-32 to develop effective treatment.

Lay Summary

Proinflammatory cytokines play an important function in mediating inflammatory reactions in chronic inflammatory diseases and in endometriosis. IL-32 is a new proinflammatory cytokine, and can also induce other proinflammatory cytokines in the body such as Tumour Necrosis Factor-α (TNF-α) and IL-8.  

This article by Lee et al. published in Human Reproduction journal from Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Seoul, Korea determined the role of IL-32 in the pathogenesis of endometriosis using endometrial cell models, human peritoneal fluid and transgenic mouse experiments, based on the emerging functions of IL-32 in several inflammatory conditions.

The study compared IL-32 levels in the peritoneal fluid between women with and without endometriosis. Peritoneal fluid was collected from advanced stage endometriosis (n = 45) and from controls (n = 40) during laparoscopic surgery. The effects of IL-32 were tested on cell viability, proliferation, and invasiveness of an endometrial adenocarcinoma cell line and endometrial stromal cells. The IL-32 function was also examined in an animal model by comparing endometriotic lesion size in IL-32 transgenic and wild-type mice after autologous endometrial transplantation. IL-32 concentration in patients peritoneal fluids were measured.

The results showed that IL-32 levels were significantly higher in the peritoneal fluid derived from endometriosis cases than the controls. Treatment of endometrial cells with IL-32 led to elevated cellular viability, proliferation, and invasiveness. Moreover, IL-32 transgenic mice had larger ectopic endometrial lesions with higher proliferative markers staining than wild-type mice. Therefore, these data suggest that IL-32 may contribute to the pathogenesis of endometriosis.

This study is supported by data from cellular, animal and human models, showing that IL-32 could play a significant role in endometriosis. Given these findings, future work will be necessary to determine whether we can target the IL-32 activity to generate new therapeutics in endometriosis.

Research Source:

endometriosis inflammation interleukin pathogenesis


Endonews is designed to strictly highlight the most recently published scientific research that focuses on endometriosis. It is not designed to provide medical advice or an opinion on the best form of treatment. We highly stress the importance of not using this site as a substitute for seeking an experienced physician, which is highly recommended if you have any questions or concerns regarding your endometriosis needs. We believe in the consciousness of our reader to discriminate that research is different than "standard of care," and trust that they can keep in mind that here at Endonews, we summarize the newest peer-reviewed scientific medical literature, without bias.